ResMed Bulls See Potential for 4Q Margin Beat -- Market Talk

Dow Jones

Jul 18, 2025

0041 GMT - ResMed's bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 17, 2025 20:41 ET (00:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552302064"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552302064\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552302064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 08:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552302064","market":"fut","top_or_hot":-1,"title":"ResMed Bulls See Potential for 4Q Margin Beat -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0041 GMT - <a href=\"https://laohu8.com/S/RMD\">ResMed</a>'s bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 20:41 ET (00:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Bulls See Potential for 4Q Margin Beat -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Bulls See Potential for 4Q Margin Beat -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-18 08:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0041 GMT - <a href=\"https://laohu8.com/S/RMD\">ResMed</a>'s bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 20:41 ET (00:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2552302064","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552302064","pubTimestamp":1752799260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0041 GMT - ResMed's bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","RMD":"瑞思迈","BK7007":"医疗保健设备","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","RMD.AU":"Resmed DRC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4504":"桥水持仓","BK7501":"新冠治疗股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4567":"ESG概念","BK4588":"碎股"},"translate_title":"瑞思迈多头看到第四季度利润率超出预期的潜力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"RMD":1},"content_text":"0041 GMT - ResMed's bulls at Jarden see potential for the breathing-tech maker's 4Q gross margin to surprise to the upside. Analysts Steve Wheen and Tristan Maher forecast on-quarter margin expansion of 20 bps, but tell clients in a note that an even greater improvement is possible. They cite manufacturing and distribution efficiencies, product mix, scale advantages and currency tailwinds as reasons for their optimism. While their 60.1% margin forecast is in line with consensus, they observe that a result of 60.5% would lift EPS by 1.3% relative to their forecasts. Jarden has an overweight rating and A$40.55 target price on the stock, which is down 0.1% at A$39.48. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2025 20:41 ET (00:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}